References
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study correspondence. Lancet Oncol. 2009;10(3):223–232. doi:https://doi.org/10.1016/S1470-2045(09)70003-8.
- Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440. doi:https://doi.org/10.1200/JCO.2002.04.117.
- Papageorgiou SG, Kontos CK, Kotsianidis I, et al. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the hellenic (Greek) MDS study group. Hematol Oncol. 2018;36(4):693–700. doi:https://doi.org/10.1002/hon.2551.
- Voso MT, Niscola P, Piciocchi A, et al. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. Eur J Haematol. 2016;96(4):344–351. doi:https://doi.org/10.1111/ejh.12595.
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. doi:https://doi.org/10.1182/blood-2009-03-209262.
- Mangi MH, Mufti GJ. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood. 1992;79(1):198–205. doi:https://doi.org/10.1182/blood.v79.1.198.bloodjournal791198.
- Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009 An International System for Human Cytogenetic Nomenclature (2009). 1 edition Basel: S. Karger; 2009.
- Greenberg BP, Cox C, Lebeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
- Greenberg PL, Tuechler H. Revised international prognostic scoring system for MDS. Blood. 2012;120(12):2454–2465. doi:https://doi.org/10.1182/blood-2012-03-420489.The.
- Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791–4797. doi:https://doi.org/10.1200/JCO.2008.16.0259.
- Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. doi:https://doi.org/10.1182/blood-2005-05-2004.
- della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441–449. doi:https://doi.org/10.3324/haematol.2010.033506.
- Magiorakos A, Srinivasan A, Carey RB, et al. Bacteria : an International expert proposal for interim standard definitions for acquired resistance. 2011.
- Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425. doi:https://doi.org/10.1182/blood-2005-10-4149.
- Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol. 2018;181(6):803–815. doi:https://doi.org/10.1111/bjh.15273.
- Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–411. doi:https://doi.org/10.1182/blood-2010-06-289280.
- Sébert M, Komrokji RS, Sekeres MA, et al. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leuk Res. 2017;63(July):72–77. doi:https://doi.org/10.1016/j.leukres.2017.10.013.
- Ferraris A, Giuntini P, Gaetani G. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979;54(4):928–932.
- Wimazal F, Sperr WR, Kundi M, et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol. 2008;19(5):970–976. doi:https://doi.org/10.1093/annonc/mdm595.
- Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian azacitidine registry of the AGMT-study group. Ann Hematol. 2014;93(11):1825–1838. doi:https://doi.org/10.1007/s00277-014-2126-9.
- Moon JH, Kim SN, Kang BW, et al. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol. 2010;89(7):681–689. doi:https://doi.org/10.1007/s00277-010-0921-5.
- Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19(12):2223–2231. doi:https://doi.org/10.1038/sj.leu.2403963.
- van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p. Br J Haematol. 2011;155(5):599–606. doi:https://doi.org/10.1111/j.1365-2141.2011.08893.x.
- Bernal T, Martínez-Camblor P, Sánchez-García J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29(9):1875–1881. doi:https://doi.org/10.1038/leu.2015.115.
- Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94(7):767–779. doi:https://doi.org/10.1002/ajh.25488.
- Feng Y, Xiong Y, Qiao T, et al. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7(12):6124–6136. doi:https://doi.org/10.1002/cam4.1820.
- Scalzulli E, Molica M, Alunni Fegatelli D, et al. Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Ann Hematol. 2019;98(8):1919–1925. doi:https://doi.org/10.1007/s00277-019-03724-9.
- Shibasaki Y, Suwabe T, Katagiri T, et al. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. Int J Hematol. 2018;108(3):282–289. doi:https://doi.org/10.1007/s12185-018-2463-x.
- Vaughn JE, Storer BE, Armand P, et al. Design and validation of an augmented hematopoietic cell transplantation-comorbidity Index comprising pretransplant ferritin, albumin, and platelet count for prediction of outcomes after allogeneic transplantation. Biol Blood Marrow Transplant. 2015;21(8):1418–1424. doi:https://doi.org/10.1016/j.bbmt.2015.04.002.
- Mądry K, Lis K, Biecek P, et al. Predictive Model for Infection Risk in myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia patients treated with azacitidine; azacitidine infection risk model: The Polish Adult Leukemia Group study. Clin Lymphoma, Myeloma Leuk. 2019;19(5):264–274. e4. doi:https://doi.org/10.1016/j.clml.2019.01.002.
- Schuck A, Goette M-C, Neukirchen J, et al. A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Ann Hematol. 2017;96(7):1097–1104. doi:https://doi.org/10.1007/s00277-017-3001-2.